934828-12-3 Usage
Uses
Used in Pharmaceutical Industry:
HDAC-IN-4 is used as a therapeutic agent for the treatment of cancer. It targets histone deacetylase enzymes, which are often dysregulated in cancer cells, leading to abnormal gene expression. By inhibiting these enzymes, HDAC-IN-4 can help restore normal gene expression patterns, potentially slowing down tumor growth and progression.
Used in Neurodegenerative Disease Treatment:
HDAC-IN-4 is used as a potential treatment for neurodegenerative diseases, such as Alzheimer's and Parkinson's, where HDAC enzymes have been implicated in the pathogenesis of these conditions. HDAC-IN-4 may help regulate gene expression related to neuroprotection and neuronal function, potentially slowing down disease progression.
Used in Inflammatory Disease Management:
HDAC-IN-4 is used as a potential therapeutic agent for inflammatory diseases, where HDAC enzymes are known to play a role in regulating inflammatory responses. By inhibiting these enzymes, HDAC-IN-4 may help modulate inflammatory pathways, reducing inflammation and alleviating disease symptoms.
Used in Drug Development Research:
HDAC-IN-4 is used as a research tool in the development of new drugs targeting HDAC enzymes. Its pharmacological properties are being studied to understand its potential effects on gene expression and its utility in treating various diseases, contributing to the advancement of medical treatments.
Check Digit Verification of cas no
The CAS Registry Mumber 934828-12-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,3,4,8,2 and 8 respectively; the second part has 2 digits, 1 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 934828-12:
(8*9)+(7*3)+(6*4)+(5*8)+(4*2)+(3*8)+(2*1)+(1*2)=193
193 % 10 = 3
So 934828-12-3 is a valid CAS Registry Number.
934828-12-3Relevant articles and documents
BENZAMIDE COMPOUNDS USEFUL AS HISTONE DEACETYLASE INHIBITORS
-
Page/Page column 41, (2010/11/27)
The invention concerns benzamide compounds of formula (I), wherein R1 is a C-linked pyrazole ring, which is optionally substituted by one or more groups selected from C1-4alkyl, C3-4cycloalkyl, C1-4alkoxy and C3-4 cycloalkoxy; or a pharmaceutically acceptable salt or pro-drug form thereof. The invention also concerns processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours or other proliferative conditions, which are sensitive to the inhibition of histone deacetylase (HDAC).
